Inclusion Criteria:

- All tumors must be ER-, PR- and HER2-negative

- Clinical stage T2 or T3, NO-3, MO. Subjects with inflammatory breast cancer are not
eligible

- For subjects with clinically negative axilla, a sentinel lymph node biopsy will be
performed either up front or after preoperative therapy at the discretion of the
subject's physicians; for subjects with a clinically positive axilla, a needle
aspiration or core biopsy will be performed to confirm the presence of metastatic
disease in the lymph nodes.

- 18 years of age or older

- Performance status of 0 or 1

- Use of an effective means of contraception in subjects of child-bearing potential

- Normal organ function as described in the protocol

Exclusion Criteria:

- Any prior cytotoxic chemotherapy or radiation for the current breast cancer

- HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of
excision alone for DCIS or breast-conserving treatment and hormonal therapy for DCIS
or invasive cancer

- Life expectancy of less than 12 weeks

- Current, recent, or planned participation in an experimental durg study other than a
Genentech-sponsored bevacizumab cancer study

- Renal dysfunction for which exposure to cisplatin would require dose modifications

- Steroid dependent asthma

- Peripheral neuropathy of any etiology that exceeds grade 1

- Uncontrolled diabetes

- History of malignancy treated without curative intent

- Any other pre-existing medical condition that would represent toxicity in excess of
grade 1

- Inadequately controlled hypertension

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- NYHA Grade II or greater congestive hear failure

- History of myocardial infarction or unstable angina within 12 months prior to study
enrollment

- Any history of stroke or transient ischemic attack at any time

- Known CNS disease

- Significant vascular disease

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury within 21 days
prior to study enrollment

- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer or bone fracture

- Proteinuria at screening

- Known hypersensitivity to any component of bevacizumab

- Pregnant or lactating